Results 211 to 220 of about 105,604 (235)

Peroxisome Proliferator-Activated Receptor-γ Expression in Lung

Chest, 2002
Ken-ichiro, Inoue, Yutaka, Kawahito, Hajime, Sano   +2 more
openaire   +2 more sources

Effects of peroxisome proliferator activated receptor-gamma 2 gene Pro12Ala polymorphism on fasting blood lipids: A meta-analysis

Atherosclerosis, 2011
Xiao Huang
exaly  

In‐vivo antioxidant and anti‐inflammatory activity of rosiglitazone, a peroxisome proliferator‐activated receptor‐gamma (PPAR‐γ) agonists in animal model of bronchial asthma

The Journal of pharmacy and pharmacology, 2015
M. El-Naa, Mohamed F. El-Refaei, W. Nasif, S. Abduljawad, A. El-brairy, M. El-Readi   +5 more
semanticscholar   +1 more source

Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice

Scandinavian Journal of Gastroenterology, 2011
Yu Jun, Suxian Zhao, Yuemin Nan
exaly  

The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial.

Journal of Clinical Endocrinology and Metabolism, 2007
A. Grey, M. Bolland, G. Gamble, D. Wattie, A. Horne, J. Davidson, I. Reid   +6 more
semanticscholar   +1 more source

MicroRNA-130b Promotes Cell Aggressiveness by Inhibiting Peroxisome Proliferator-Activated Receptor Gamma in Human Hepatocellular Carcinoma

International Journal of Molecular Sciences, 2014
Qingguang Liu, Kangsheng Tu, Xin Zheng   +2 more
exaly  

[Peroxisome proliferator-activated receptor gamma (PPAR gamma)].

Nihon rinsho. Japanese journal of clinical medicine, 2001
E, Sugiyama, N, Tanaka, T, Aoyama
openaire   +1 more source

Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) as a Target for Concurrent Management of Diabetes and Obesity-Related Cancer

Current Pharmaceutical Design, 2017
Fudi Wang, Mustapha Umar İmam
exaly  

Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis

Current Pharmaceutical Design, 2017
Veronika Myasoedova, Alexander Orekhov, Alexandra Melnichenko   +2 more
exaly  

Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.

Diabetes, 2003
D. Savage, G. Tan, C. Acerini, S. Jebb, M. Agostini, M. Gurnell, Rachel L. Williams, A. Umpleby, Elizabeth Louise Thomas, Jimmy D Bell, A. Dixon, F. Dunne, R. Boiani, S. Cinti, A. Vidal-Puig, F. Karpe, V. Chatterjee, S. O’Rahilly   +17 more
semanticscholar   +1 more source